Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-138943

Published: 2020

Journal Articles

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Donna L. Forrest, MD, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Mary-Margaret Keating, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-136163

Published: 2020

Journal Articles

Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients

Tracy Murphy, MDFRCP,FRCPath, Stanley W.K. Ng, PhD, Tong Zhang, Ian King, PhD, Andrea Arruda, Jaime O. Claudio, PhD, Narmin Ibrahimova, Fiona Ferrera, Chantal Rockwell, Zhibin Lu, Natalie Stickle, Carl Virtanen, MSc, Brian Leber, MD, Mitchell Sabloff, MD, Mark D. Minden, MD PhD, Tracy L. Stockley, PhD FCCMG, FACMG, Steven M Chan, MD PhD, Jean C.Y. Wang, MD

Blood (2019) 134 (Supplement_1): 2682.

https://doi.org/10.1182/blood-2019-130532

Published: 2019

Journal Articles

High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1424.

https://doi.org/10.1182/blood-2019-122890

Published: 2019

Journal Articles

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 3317.

https://doi.org/10.1182/blood-2019-125780

Published: 2019

Journal Articles

Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML

Robert Puckrin, MD, Eshetu G Atenafu, M.Sc., P.Stat, Jaime Claudio, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Mark D. Minden, MD PhD, Andre Schuh, Tracy Murphy, MDFRCP,FRCPath, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Aaron D Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 436.

https://doi.org/10.1182/blood-2018-99-113090

Published: 2018

Journal Articles

Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations

Tracy Murphy, MDFRCP,FRCPath, Jinfeng Zou, PhD, Georgina S Daher-Reyes, MD, Vikas Gupta, MD FRCP, FRCPath, Caroline J McNamara, MBBS, Mark D. Minden, MD PhD, Aaron D Schimmer, MD PhD, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Dawn Maze, MDFRCPC,MSc, Scott Bratman, MD PhD, Andre Schuh, Steven M Chan, MD PhD

Blood (2018) 132 (Supplement 1): 992.

https://doi.org/10.1182/blood-2018-99-115518

Published: 2018

Journal Articles

Impact of Genetic Profile on Clinical Outcomes in Adults ≥60 with AML: The Princess Margaret Cancer Centre Experience

Georgina S Daher-Reyes, MD, Caroline J McNamara, MBBS, Manjula Maganti, MSc, Tracy L. Stockley, PhD FCCMG, FACMG, Jose Mario Capo-Chichi, PhD FACMG, Reem Abdulrahman Alkharras, Andrea Arruda, Jaime Claudio, Steven M Chan, MD PhD, Aaron D Schimmer, MD PhD, Mark D. Minden, MD PhD, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Vikas Gupta, MD FRCP, FRCPath, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Dawn Maze, MD FRCPC, MSc, Andre Schuh

Blood (2018) 132 (Supplement 1): 2666.

https://doi.org/10.1182/blood-2018-99-118938

Published: 2018

Journal Articles

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Arjun Datt Law, MBBS, MDDM, Mahadeo A. Sukhai, BSc, MSc, PhD, Mariam Thomas, PhD, Andrea Arruda, MSc., Narmin Ibrahimova, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Hassan Sibai, MD, Karen W.L. Yee, MD, Dwayne L. Barber, PhD, Tracy L. Stockley, PhD, Suzanne Kamel-Reid, PhD DABMG, FACMG, Andre C. Schuh, MD FRCPC

Blood (2016) 128 (22): 2886.

https://doi.org/10.1182/blood.V128.22.2886.2886

Published: 2016

Journal Articles

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Blood (2016) 128 (22): 4263.

https://doi.org/10.1182/blood.V128.22.4263.4263

Published: 2016

Journal Articles

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

Blood (2015) 126 (23): 3848.

https://doi.org/10.1182/blood.V126.23.3848.3848

Published: 2015

NARROW

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients

High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML

Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations

Impact of Genetic Profile on Clinical Outcomes in Adults ≥60 with AML: The Princess Margaret Cancer Centre Experience

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only